Physician profile
Mark A Gendal
NPI 1629167150
$4,119.55
in general payments reported to CMS, 2019-2025
14 companies · $385 in 2025
The $385 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $844 · 2020: $175 · 2021: $419 · 2022: $862 · 2023: $717 · 2024: $718 · 2025: $385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,820.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,819.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,607.12 | 2022-2025 | Infuse, Miebo |
| Johnson & Johnson Vision Care, INC. | $998.36 | 2019-2024 | Acuvue |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $426.96 | 2019-2021 | |
| Abb Con-Cise Optical Group LLC | $375.52 | 2019-2025 | Contact Lens |
| Maculogix, INC. | $159.69 | 2019 | |
| Glaukos Corporation | $150.34 | 2025 | Kxl System (Not Refurbished) |
| Genentech USA, INC. | $136.56 | 2019 | |
| Coopervision INC. | $116.06 | 2023-2025 | Onefit Contact Lens, Misight Contact Lens |
| Novartis Pharmaceuticals Corporation | $39.16 | 2020-2021 | |
| Tarsus Pharmaceuticals, INC. | $32.19 | 2024 | Xdemvy |
| Shire North American Group INC | $22.98 | 2019 | |
| Alcon Vision LLC | $22.92 | 2023 | Total30 |
| Oyster Point Pharma, INC. | $19.73 | 2022 | |
| Visioneering Technologies, INC. | $11.96 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Gendal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.